Journal of Clinical Oncology
Articles in this Issue
Patient (pt) characteristics, treatment patterns, and outcomes in unresectable hepatocellular carcinoma (uHCC) treated with first-line (1L) systemic therapy in the United States (US).
e16167 Background: Guidelines recommend systemic therapy for uHCC ineligible for locoregional therapy. Until the approval of tremelimumab + durvalumab for...
Survival of patients (pts) with microsatellite stable/mismatch repair proficient (MSS/pMMR) metastatic colorectal carcinoma (mCRC) treated with EO4010 + nivolumab (EO/N).
3536 Background: EO is designed to expand pre-existing memory CD8 T cells cross-reacting with tumor associated antigens (TAAs). EO is composed of microbia...
Assessing the influence of neutropenia severity on mortality and adverse outcomes in chemotherapy-related septic shock.
e15018 Background: Neutropenia, a common complication in cancer patients undergoing chemotherapy, significantly increases the risk of severe infections, i...
Efficacy and CNS results from a randomized subset of the phase 2 SAVANNAH study comparing savolitinib (savo) + osimertinib (osi) combination with savo + placebo (PBO).
8513 Background: The MET pathway is a known mediator of EGFR-TKI resistance and represents a therapeutic vulnerability to select MET-TKIs. Savo is an oral...
Vulnerability cartography: A narrative review of the historical, epidemiological, and biocultural perspectives of cancer in indigenous women in Brazil over the last three decades.
e22533 Background: The global indigenous population in 2021 is around 476 million in 90 countries, with lower life expectancy, cultural diversity and high...
Efficacy of low-dose dasatinib (50mg) in chronic myeloid leukemia: Chronic phase (CML-CP) in LMIC—Are we there yet?
e18571 Background: Worldwide, the literature on low-dose Dasatinib (50 mg) in CML-CP shows comparable efficacy with enhanced tolerance and fewer treatment...
GUIDE-T: A three-tier, markmap-driven platform for streamlined breast cancer trial navigation and improved enrollment.
e23022 Background: Clinical trial enrollment in Breast Cancer (BC) remains challenging due to frequent changes in protocol status, extensive eligibility c...
Optimizing board exam outcomes: A structured exam preparation curriculum for hematology/oncology fellows.
e21011 Background: The increasing complexity of Hematology and Oncology necessitates board-certified specialists to ensure baseline clinical competence. H...
Use of an ultra-sensitive sequencing platform to detect mutant <i>KRAS</i> in the whole blood of pancreatic cancer patients.
4156 Background: Pancreatic Ductal Adenocarcinoma (PDAC) is a leading cause of cancer death and mortality is increasing. A contributor to poor outcomes is...
Clinical treatment patterns and patient characteristics in the advanced and metastatic esophageal cancer (EC) population treated in the hospitals from county or prefecture-level cities in high-prevalence areas of China: Real-world data.
e16039 Background: About half of the newly diagnosed esophageal cancer (EC) cases worldwide occur in China each year. The distribution of EC patients (pts...
Patient perspectives on nonmelanoma skin cancer care: Insights into treatment, barriers, and healthcare gaps.
e21015 Background: Nonmelanoma skin cancer (NMSC), comprised mainly of cutaneous squamous cell (CSCC) and basal cell (BCC) carcinomas, represent the most...
FIRST-NEC (GFPC 01-2022): A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab with etoposide and platinum as first line treatment in patients with advanced large-cell neuroendocrine lung carcinomas (LCNECs).
TPS8657 Background: LCNECs of the lung are rare lung tumors (2%) with difficult histopathological diagnosis (70-80% confirmation rate after centralized re...
Trifluridine tipiracil with bevacizumab in refractory metastatic colorectal cancer with a convenient two weekly schedule: An Indian single center experience.
e15612 Background: Refractory metastatic colorectal cancer (CRC) is a challenging situation with most patients showing modest response to treatment with t...
MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: Primary endpoints of the phase 3 MIDAS trial.
7500 Background: The phase III IFM2020-02-MIDAS study (NCT04934475) evaluated a minimal residual disease (MRD)-driven consolidation and maintenance strate...
Clinical trial challenges in LMIC.
e23025 Background: Clinical trials are crucial for advancing medical knowledge and creating novel therapeutic interventions; however, they also present se...
Long-term follow-up of treatment-free remission in chronic myeloid leukemia after discontinuation of tyrosine kinase inhibitor therapy.
6566 Background: Treatment-free remission (TFR) is an important goal of therapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP)....
A clinical risk scoring system for the prediction of early infection after CAR-T therapy.
e23330 Background: CAR-T therapy has transformed the management of hematologic malignancies but is often complicated by severe infections, a leading cause...
Telehealth and cancer care delivery: An updated real-world analysis of the impact of telehealth on patient access and treatment utilization at a comprehensive cancer center.
1644 Background: Telehealth in oncology (onc) has persisted due to its convenience and potential to improve equitable access to care. Data on telehealth’s...
Out of touch: Understanding the frequency and trajectory of chemotherapy-induced neuropathy peripheral (CIPN) in breast cancer survivors.
12038 Background: CIPN, primarily associated with sensory neuropathy rather than motor or autonomic dysfunction, is a potentially long-term complication o...
Impact of sample characteristics on RNA-based next-generation sequencing (NGS) for fusion gene detection in non-small cell lung cancer (NSCLC).
3132 Background: RNA-based next-generation sequencing (NGS) has been widely employed for detecting fusion genes in NSCLC, due to its superior sensitivity...
Clinical performance of Signatera Genome assay in a cohort of patients (pts) with solid tumors.
3142 Background: Circulating tumor DNA (ctDNA) has emerged as a powerful, minimally invasive biomarker of treatment respon...
Macroscale genomic alterations in histomolecular invasive lobular carcinoma compared to other breast cancer subtypes.
1049 Background: Although invasive lobular carcinoma (ILC) is often classified as a separate breast cancer (BC) subtype with distinct molecular features,...
Utilizing targeted intra-tumoral hyperthermia as an immunotherapy in immunogenically ‘cold’ tumor models.
2581 Background: Hyperthermia is an established adjunct in multimodal cancer treatments, with mechanisms including cell death, immune modulation, and vasc...
Non-infectious sarcoid-like inflammatory granulomatous conditions (NSIGC) associated with immune checkpoint inhibitors (ICIs) for cancer: Results from the International ICARUS (Immune Checkpoint Associated Rare and Unique Side effects) consortium.
12047 Background: ICIs can be associated with a broad range of toxicities; however, limited data exists on NSIGC secondary to ICIs. Herein, we assembled t...
Methodology for estimation of progression-free survival in patients with non-small cell lung cancer using real-world data from a French cohort.
e23302 Background: RECIST is the gold standard for evaluating tumor response, but in clinical practice, patient assessments are not always precisely timed...